

# Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), And Segment Forecasts, 2018 - 2025

<https://marketpublishers.com/r/P43CC0C275DEN.html>

Date: October 2018

Pages: 65

Price: US\$ 5,950.00 (Single User License)

ID: P43CC0C275DEN

## Abstracts

This report can be delivered to the clients within 48 Business Hours

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 5.8 billion by 2025 at a 11.2% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Several factors such as rise in number of blood and bone marrow related disorders, increase in geriatric population, wider adoption of novel therapeutics, and emergence of biologics are driving the market.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder. It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe. The life-threatening disease often manifests in three forms: thrombosis, persistent intravascular hemolysis, and pancytopenia. Although information on its prevalence is scarce, PNH is estimated to affect more than 20,000 people worldwide with an incidence of about 1.3 per million annually and a prevalence of around 16 per million. PNH affects men and women equally. Although physical symptoms can begin at any age, they usually develop between 30-40 years of age.

Novel treatments including monoclonal antibodies, recombinant proteins, and cyclic peptides are gaining penetration in developed markets. However, high cost of therapy with Soliris and other emerging pipeline drugs presents a barrier in adoption in developing regions. Blood transfusion and supportive care are anticipated to lose

momentum during the forecast period due to adverse side effects and sub-optimal efficacy.

Further key findings from the report suggest:

An estimated 5,000 - 6,000 people in U.S. suffer from PNH, with approximately 450 new cases being reported annually

U.S. dominated the global PNH treatment market with more than 35% share in 2017 due to high cost of treatment in U.S., potential approval of a range of pipeline drugs, and adoption of novel therapeutics

Treatment with medication dominated the PNH market with a share of more than 75% in 2017. Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period

Alexion, Akari, Apellis, Amgen, CinnaGen, Ra Pharmaceuticals, Alnylam, Achillion, Novartis, Roche, and Regeneron Pharmaceuticals are some of the key players in this market

Currently, 16 products are under clinical evaluation for PNH treatment in various stages of development. Promising pipeline candidates such as ALXN1210, Coversin, APL2, and RA101495 offer significant commercial potential post regulatory approval.

## Contents

### **CHAPTER 1 REPORT SCOPE**

- 1.1 Treatment Scope
- 1.2 Country Scope
- 1.3 Estimates and Forecast Timeline

### **CHAPTER 2 METHODOLOGY**

- 2.1 Research Methodology
  - 2.1.1 Information procurement
- 2.2 Information or Data Analysis
- 2.3 Market Formulation & Validation
- 2.4 List of Sources
- 2.5 List of Abbreviations

### **CHAPTER 3 OBJECTIVES**

- 3.1 Objective - 1: Understanding the market dynamics
- 3.2 Objective - 2: Understanding the trends & variables in the individual countries
- 3.3 Objective - 3: Understanding the attributes such as strategy framework
- 3.4 Objective - 4: Understanding the key service and application scopes

### **CHAPTER 4 EXECUTIVE SUMMARY**

### **CHAPTER 5 DISEASE PRIMER AND EPIDEMIOLOGY**

- 5.1 Disease Primer
- 5.2 Epidemiology
  - 5.2.1 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
  - 5.2.2 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
    - 5.2.2.1 U.S.
    - 5.2.2.2 Japan
    - 5.2.2.3 U.K.
    - 5.2.2.4 Germany
    - 5.2.2.5 France
    - 5.2.2.6 Spain
    - 5.2.2.7 Italy

#### 5.2.2.8 RoW

## **CHAPTER 6 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET OVERVIEW**

### 6.1 Market, by Treatment

#### 6.1.1 Medication

#### 6.1.2 Stem Cell Transplant (SCT)

#### 6.1.3 Blood Transfusion

### 6.2 Market, by Country

#### 6.2.1 U.S.

#### 6.2.2 Japan

#### 6.2.3 U.K.

#### 6.2.4 Germany

#### 6.2.5 France

#### 6.2.6 Spain

#### 6.2.7 Italy

#### 6.2.8 RoW

### 6.3 Market Size & Forecast

#### 6.3.1 Sales Performance

##### 6.3.1.1 Sales Performance, by Treatment (2017 - 2025)

##### 6.3.1.2 Sales Performance, by country (2017 - 2025)

### 6.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Drivers and Restraints

### 6.5 M & A, Deal Landscape (2014-2018 YTD)

### 6.6 SWOT

## **CHAPTER 7 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: PIPELINE INTELLIGENCE**

### 7.1 Pipeline Landscape

#### 7.1.1 Leading Drugs in Development

#### 7.1.2 Key R & D Trends

### 7.2 Promising Drug Candidates in Pipeline

#### 7.2.1 Late Stage Pipeline Analysis

#### 7.2.2 Profile of Disruptive Drugs

### 7.3 Global Pipeline Forecast

## **CHAPTER 8 COMPANY PROFILES**

- 8.1 Alexion Pharmaceuticals
  - 8.1.1 Company Overview
  - 8.1.2 Current Product Portfolio- Major Products
  - 8.1.3 Product Forecast Sales up to 2025
  - 8.1.4 Strategic Initiatives
    - 8.1.4.1 Key Company News Flow
  - 8.1.5 SWOT
- 8.2 Akari Therapeutics
  - 8.2.1 Company Overview
  - 8.2.2 Current Product Portfolio- Major Products
  - 8.2.3 Product Forecast Sales up to 2025
  - 8.2.4 Strategic Initiatives
    - 8.2.4.1 Key Company News Flow
  - 8.2.5 SWOT
- 8.3 Apellis Pharmaceuticals
  - 8.3.1 Company Overview
  - 8.3.2 Current Product Portfolio- Major Products
  - 8.3.3 Product Forecast Sales up to 2025
  - 8.3.4 Strategic Initiatives
    - 8.3.4.1 Key Company News Flow
  - 8.3.5 SWOT
- 8.4 Ra Pharmaceuticals
  - 8.4.1 Company Overview
  - 8.4.2 Current Product Portfolio- Major Products
  - 8.4.3 Strategic Initiatives
    - 8.4.3.1 Key Company News Flow
  - 8.4.4 SWOT

## **CHAPTER 9 MARKET OUTLOOK**

- 9.1 Winners and Losers
- 9.2 Emerging Companies
- 9.3 What the Future Holds

## List Of Tables

### LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviation

Table 3 Forecast Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence and Incidence, 2017 - 2025

Table 4 Sales Performance, by Treatment (in \$ Million)

Table 5 Sales Performance, by Country (in \$ Million)

Table 6 Paroxysmal Nocturnal Hemoglobinuria (PNH) R & D Pipeline - Drugs in Development

Table 7 R & D Pipeline Overview

Table 8 Late Stage Pipeline

Table 9 Product Profile: Soliris (eculizumab)

Table 10 Product Profile: ALXN1210 (ravulizumab)

Table 11 Product Profile: Coversin (nomacopan)

Table 12 Product Profile: APL2

Table 13 Product Profile: RA101495

Table 14 Product Profile: Cemdisiran (ALN-CC5)

Table 15 Product Profile: ACH-4471

Table 16 Product Profile: LFG316 (tesidolumab)

Table 17 Product Profile: RO7112689 (SKY59)

Table 18 Global Pipeline Forecast

Table 19 Product Portfolio: Soliris (eculizumab)

Table 20 Soliris (eculizumab) Sales Forecast, 2017- 2025 (in \$ Million)

Table 21 Product Portfolio: ALXN1210 (ravulizumab)

Table 22 ALXN1210 (ravulizumab) Sales Forecast, 2017- 2025 (in \$ Million)

Table 23 Product Portfolio: Coversin (nomacopan)

Table 24 Coversin (nomacopan) Sales Forecast, 2017- 2025 (in \$ Million)

Table 25 Product Portfolio: APL2

Table 26 APL2 Sales Forecast, 2017- 2025 (in \$ Million)

Table 27 Product Portfolio: RA101495

Table 28 RA101495 Sales Forecast, 2017- 2025 (in \$ Million)

## List Of Figures

### LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value chain based sizing & forecasting
- Fig. 6 QFD modelling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Segmentation
- Fig. 9 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Outlook: Key Takeaways
- Fig. 10 Current Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence Across Seven Major Markets - 2017
- Fig. 11 Current Paroxysmal Nocturnal Hemoglobinuria (PNH) Incidence Across Seven Major Markets - 2017
- Fig. 12 U.S. Forecast Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence (2017 - 2025)
- Fig. 13 Japan Forecast Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence (2017 - 2025)
- Fig. 14 U.K. Forecast Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence (2017 - 2025)
- Fig. 15 Germany Forecast Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence (2017 - 2025)
- Fig. 16 France Forecast Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence (2017 - 2025)
- Fig. 17 Spain Forecast Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence (2017 - 2025)
- Fig. 18 Italy Forecast Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence (2017 - 2025)
- Fig. 19 RoW Forecast Paroxysmal Nocturnal Hemoglobinuria (PNH) Prevalence (2017 - 2025)
- Fig. 20 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share, by Treatment (2017 & 2025)
- Fig. 21 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share, by Country (2017 & 2025)
- Fig. 22 U.S. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, \$ Million

(2017 - 2025)

Fig. 23 Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, \$ Million

(2017 - 2025)

Fig. 24 U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, \$ Million

(2017 - 2025)

Fig. 25 Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, \$

Million (2017 - 2025)

Fig. 26 France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, \$

Million (2017 - 2025)

Fig. 27 Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, \$ Million

(2017 - 2025)

Fig. 28 Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, \$ Million

(2017 - 2025)

Fig. 29 RoW Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, \$ Million

(2017 - 2025)

Fig. 30 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size &

Forecast, \$ Million (2017 - 2025)

Fig. 31 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market SWOT

Fig. 32 SWOT Analysis (Alexion Pharmaceuticals)

Fig. 33 SWOT Analysis (Akari Therapeutics)

Fig. 34 SWOT Analysis (Apellis Pharmaceuticals)

Fig. 35 SWOT Analysis (Ra Pharmaceuticals)



## I would like to order

Product name: Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), And Segment Forecasts, 2018 - 2025

Product link: <https://marketpublishers.com/r/P43CC0C275DEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P43CC0C275DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970